About Papyrus DX
Papyrus DX is a Healthcare company based in Bengaluru (India) founded in 2021 by Venkata Subramanian Ramesan and Bhushan Toley. It operates as a diagnostic devices for infectious diseases and antimicrobial resistance are developed. The company has 1 employees. Its chief executive is Venkata Subramanian Ramesan. Its Indian entity Papyrus Diagnostics Private Limited reported revenue of ₹4.3 Lakh. Its focus areas include Life Sciences, Infectious Diseases, Medical Devices and Screening. Its competitors include RAMJA Genosensor, phenofAST, MedFluid and OSPT; 1 of its 4 listed competitors has raised funding.
Company details
Papyrus was founded in 2021 in Bengaluru, India, within the health technology sector. Diagnostic solutions for detecting antimicrobial resistance, COVID-19, and other infectious diseases are offered. Specimen transport technology is also provided to support these operations. The focus remains on advancing point-of-care diagnostics for global health challenges, with activities centered in the Indian market.
- Headquarters Bengaluru, India
- Employees 1
- Founders Venkata Subramanian Ramesan, Bhushan Toley
- SectorsHealthcare
- Website papyrusdx.com
- Legal Name Papyrus Diagnostics Private Limited
- Date of Incorporation 07 Jul, 2021
- Jurisdiction Bangalore, Karnataka, India
- Annual Revenue₹4.3 Lakh
FY 2025 · +288% YoY
- Net Loss-₹2.3 Lakh
FY 2025 · -53% margin
- EBITDA-₹1.9 Lakh
FY 2025 · -44% margin
- Employee Count1
Associated legal entities of Papyrus DX
Papyrus DX operates through Papyrus Diagnostics Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Papyrus Diagnostics Private Limited CIN U33119KA2021PTC149168 | Active | 07 Jul 2021 | Bangalore, Karnataka | ₹0.0 Cr | – | 2 | View details |
Board of directors of Papyrus Diagnostics Private Limited (Papyrus DX)
Papyrus Diagnostics Private Limited is the primary company behind Papyrus DX. The board of Papyrus Diagnostics Private Limited currently have 2 directors; the longest-serving is Bhushan Toley, appointed in 2021. 2 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Bhushan Toley DIN 09229726 | Director | 07 Jul 2021 | 5 yrs 3 mo | Papyrus Diagnostics Private Limited |
| Venkata Subramanian DIN 09229727 | Director | 07 Jul 2021 | 5 yrs 3 mo | Papyrus Diagnostics Private Limited |
People of Papyrus DX
2 people are tracked at Papyrus DX (2 in leadership); the tracked headcount is 1.
| Name | Role | Group |
|---|---|---|
Venkata Subramanian Ramesan | Co-Founder & CEO | Leadership |
| Co-Founder | Leadership |
Complete people profiles for Papyrus DX
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Papyrus DX
Figures of Papyrus Diagnostics Private Limited, the primary company behind Papyrus DX, for FY 2025. Revenue was ₹4.3 Lakh (+288% year on year). Net loss was -₹2.3 Lakh (-53% margin). EBITDA was -₹1.9 Lakh (-44% margin).
- ₹4.3 LakhRevenue · FY 2025 · +288% YoY
- -₹2.3 LakhNet loss · -53% margin
- -₹1.9 LakhEBITDA · -44% margin
- ₹11,110Paid-up capital
Balance sheet, profit and loss, cash flow and ratios of Papyrus Diagnostics Private Limited are on its company page.
Detailed financial statements for Papyrus DX
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Competitors of Papyrus DX
Papyrus DX has 4 listed competitors in our database, 1 of them funded. They include RAMJA Genosensor, phenofAST, MedFluid and OSPT, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ramjagenosensor.com | 2018 | Delhi, India | $24,016 | – | Developer of a smart sensor for the detection of bacterial infection and antibiotic resistance | |
| phenofast.com | 2018 | Haifa, Israel | – | – | Provides comprehensive solutions for antimicrobial susceptibility testing. | |
| medfluid.com.tw | 2019 | Hsinchu, Taiwan | – | – | Provides point-of-care molecular diagnostics and antimicrobial susceptibility testing solutions. | |
| oxfordsilkphages.co.uk | 2020 | Oxford, United Kingdom | – | – | Pioneering antibacterial textiles to combat surgical implant and wound infections. |
Detailed competitors of Papyrus DX
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Infectious Diseases
10 companies that operate in the same segment as Papyrus DX (Infectious Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 | |
Clinical diagnostics and drug discovery for immune diseases are provided. | 2009 | Seattle, Washington, United States | USD 419.15 M | USD 276.98 M | 619 | |
Vaccines for infectious diseases are developed using cell-free protein synthesis. | 2013 | Foster City, California, United States | USD 347 M | – | 414 | |
Portable PCR diagnostics for infectious diseases are developed. | 2010 | San Jose, California, United States | USD 386.33 M | – | 172 | |
Developing glucan synthase inhibitors for the treatment of fungal infections. | 1999 | Jersey City, New Jersey, United States | USD 62.65 M | USD 20.6 M | 28 | |
Sherlock Biosciences is focused on molecular diagnostics development. | 2019 | Watertown, United States | USD 111 M | – | 33 | |
Provider of diagnostic solutions for systemic infections | 2016 | San Francisco, California, United States | USD 191.47 M | – | 54 | |
Developer of novel protein-based therapeutics using machine learning and biological engineering | 2018 | Somerville, Massachusetts, United States | USD 693 M | – | 329 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Papyrus DX
Papyrus DX was founded in 2021.
Papyrus DX is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
Venkata Subramanian Ramesan is the current CEO of Papyrus DX. They have also founded this company.
Papyrus DX has 1 employees.
The primary company behind Papyrus DX, Papyrus Diagnostics Private Limited, reported revenue of ₹4.3 Lakh for FY 2025, up 288% year on year.
Papyrus was founded in 2021 in Bengaluru, India, within the health technology sector. Diagnostic solutions for detecting antimicrobial resistance, COVID-19, and other infectious diseases are offered. Specimen transport technology is also provided to support these operations. The focus remains on advancing point-of-care diagnostics for global health challenges, with activities centered in the Indian market.
Papyrus DX's top competitors include RAMJA Genosensor, phenofAST and MedFluid.
Papyrus DX operates through Papyrus Diagnostics Private Limited.
The legal entities of Papyrus DX currently have 2 directors, including Bhushan Toley, Venkata Subramanian.